Modulight Bio
Tel Aviv, Israel· Est.
Israeli optogenetics biotech leveraging light‑controlled GPCRs to treat refractory neurological disorders.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $12M
AI Company Overview
Israeli optogenetics biotech leveraging light‑controlled GPCRs to treat refractory neurological disorders.
NeurologyPainEpilepsyMovement Disorders
Technology Platform
A gene‑therapy‑delivered bistable inhibitory GPCR opsin (eOPN3) combined with implantable light devices to achieve reversible, on‑demand silencing of overactive neurons.
Opportunities
First‑in‑human trials could unlock a new class of reversible, gene‑therapy‑based neuromodulation for refractory neurological disorders, tapping a multi‑billion‑dollar market.
Risk Factors
Technical challenges in safe gene‑vector delivery, long‑term device biocompatibility, and regulatory approval for combined gene‑therapy/optical products.
Competitive Landscape
Competitors such as NeuroPace, SetPoint Medical, and Magnetogenics focus on electrical or magnetic neuromodulation; Modulight differentiates with optogenetic precision and reversible GPCR‑mediated inhibition.